Cargando…
AMD3100/CXCR4 Inhibitor
Autor principal: | De Clercq, Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459229/ https://www.ncbi.nlm.nih.gov/pubmed/26106388 http://dx.doi.org/10.3389/fimmu.2015.00276 |
Ejemplares similares
-
CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011) -
V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
por: Maeda, Yosuke, et al.
Publicado: (2014) -
CXCR4 Antagonist AMD3100 Modulates Claudin Expression and Intestinal Barrier Function in Experimental Colitis
por: Xia, Xian-Ming, et al.
Publicado: (2011) -
The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
por: Kim, Ha-Yon, et al.
Publicado: (2010) -
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US
Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)